1 / 13

Update on the OIG’s Investigations Involving Clinical Research

Update on the OIG’s Investigations Involving Clinical Research. Or, What is the OIG Worrying About Now and Why?. Medical Research Summit 2002 Washington, DC Mark R. Yessian, PhD Regional Inspector General Office of Inspector General U.S. Dept. of Health and Human Services.

etana
Download Presentation

Update on the OIG’s Investigations Involving Clinical Research

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Update on the OIG’s Investigations Involving Clinical Research Or, What is the OIG Worrying About Now and Why? Medical Research Summit 2002 Washington, DC Mark R. Yessian, PhD Regional Inspector General Office of Inspector General U.S. Dept. of Health and Human Services

  2. Question #1: What is the OIG’s Role? • Independent oversight • Assess effectiveness and efficiency

  3. Question #2: What is the OIG’s Track Record in this Field? • An extensive review of IRBS and human subject protections • Issuance of 10 reports (www.oig.hhs.gov) • Testimony at 3 Congressional hearings • Site visits to 25-30 IRBs • Presentations at 40-50 professional meetings

  4. Question #3: Why has the OIG Become so Interested in Human Subject Protections? • 1995 study on investigational devices raised questions about the continuing review role of IRBs • Led to broadly based inquiry of challenges facing IRBs • June 1998 issuance of high-profile reports on IRBs

  5. June 1998 Report IRBS: A Time for Reform • IRBs review too much, too quickly, with little expertise • They conduct minimal review of approved research • They face conflicts that threaten their independence • They provide little training for investigators and board members • Neither IRBs nor HHS devote much attention to evaluating the effectiveness of IRBs

  6. Reactions to the Report • Raised much concern in the professional community • Helped spark some reform

  7. Subsequent OIG Reports • Recruiting Human Subjects • Globalization of Clinical Trials • Clinical Trial Web Sites (To be released this spring)

  8. With Respect to Human Subject Protections, What is the OIG Worrying About Now and Why? • Sustaining a capacity for independent review • Strengthening continuing review

  9. Sustaining a Capacity for Independent Review • Enduring pressures on IRBs • Continuing resource constraints • Evolving emphasis on responsibility of investigators

  10. Sustaining a Capacity for Independent Review (cont.) • Maintaining sufficient expertise • Limited organizational independence • Minimal outside representation

  11. Strengthening Continuing Review • Looking to informed consent as a process, not just a form • Examining how the recruitment process really works

  12. Strengthening Continuing Review (cont.) • Ensuring the continued safety of subjects • making sense of adverse event reports • determining the role of data safety monitoring boards

  13. From “Trust” to “Trust but verify”

More Related